Sirolimus enhances the protection achieved by a DNA vaccine against Leishmania infantum.

ABSTRACT:

Background

Leishmaniases are a group of neglected tropical parasitic diseases, mainly affecting vulnerable populations of countries with poor socioeconomic status. Development of efficient vaccines is a priority due to the increasing incidence of drug resistance and toxicity to current treatments. In the search for a safe and efficient protective vaccine for human and dog visceral leishmaniases, we analyzed the suitability of the immunomodulatory drug sirolimus (SIR) to boost a preventive DNA vaccine against leishmaniasis. SIR is an already marketed drug that has been described to boost immune protection against different disease models and has also emerged as a promising therapeutic drug against L. major.

Methods

Syrian hamsters were treated with SIR concomitantly with the

SUBMITTER: Martinez-Florez A 

PROVIDER: S-EPMC7282043 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature